Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20 studies found for:    "Plasma cell leukemia"
Show Display Options
Download search resultsDownload the search results for:
"Plasma cell leukemia" (20 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia
Condition: Primary Plasma Cell Leukemia
Intervention: Drug: Lenalidomide, dexamethasone
2 Unknown  Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Conditions: Plasma Cell Leukemia;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Liposome doxorubicin;   Drug: Dexamethasone
3 Recruiting Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Conditions: Plasma Cell Leukemia;   Plasma Cell Myeloma;   Plasmacytoma
Interventions: Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Pomalidomide
4 Completed
Has Results
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: PBSCT
5 Completed Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70
Condition: Multiple Myeloma
Intervention: Drug: PAD-VCD
6 Completed A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous;   Drug: Dexamethasone, steroid; oral;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
7 Recruiting Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Conditions: Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Biological: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
8 Withdrawn Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Intervention: Drug: Bendamustine
9 Completed A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;   Drug: Dexamethasone, steroid; oral
10 Terminated
Has Results
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine/Busulfan x 4 days;   Procedure: stem cell transplant
11 Recruiting SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Conditions: Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
Interventions: Biological: Incomplete Freund's Adjuvant;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Sargramostim;   Biological: SVN53-67/M57-KLH Peptide Vaccine
12 Unknown  Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse;   Mantle Cell Lymphoma in Relapse;   Diffuse Large B Cell Lymphoma in Relapse;   Other B Cell Lymphoma in Relapse;   Plasma Cell Leukemia
Intervention: Biological: SNS01-T
13 Terminated
Has Results
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Conditions: Multiple Myeloma;   Leukemia, Plasma Cell
Interventions: Drug: Carfilzomib;   Drug: Melphalan;   Drug: Filgrastim
14 Completed Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: bortezomib;   Drug: dexamethasone;   Drug: thalidomide;   Drug: Aspirin
15 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
16 Not yet recruiting Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
17 Not yet recruiting Allo HSCT Using RIC for Hematological Diseases
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
Interventions: Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
18 Recruiting Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Conditions: Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Myeloproliferative Disorders;   Multiple Myeloma;   Plasma Cell Neoplasm;   Plasma Cell Dyscrasia;   Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
19 Active, not recruiting Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Conditions: Adult Acute Myeloid Leukemia in Remission;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndrome;   Childhood Renal Cell Carcinoma;   Chronic Myelomonocytic Leukemia;   Clear Cell Renal Cell Carcinoma;   de Novo Myelodysplastic Syndrome;   Metastatic Renal Cell Cancer;   Previously Treated Myelodysplastic Syndrome;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Renal Medullary Carcinoma;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Fludarabine Phosphate;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
20 Active, not recruiting Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim

Study has passed its completion date and status has not been verified in more than two years.